Intratumoral CCL21 and checkpoint blockade cooperatively inhibit NSCLC tumor growth in vivo to a greater extent than either monotherapy alone

IC50), but high dose EN460 didn’t sensitize cells to CDDP. In summary, high ERO1L expression was associated with poor prognosis of non-small cell lung cancer and resistance to CDDP therapy, which may be ameliorated with addition of EN460. These data suggest that ERO1L may promote lung cancer cell survival and resistance to chemotherapy by reduction of ER stress, and that ERO1L inhibitor may sensitize CDDP-resistant cancer cells to CDDP.